Genmab (CPSE:GMAB) Could Be 15% Undervalued After Its Recent Rebound
Genmab (CPSE:GMAB) has caught investor attention after a recent swing that left the share price at DKK 2,083. The move comes against a mixed backdrop of short term declines and longer term gains.
Recent trading tells a mixed story. The share price has slipped over the past week but still shows a 30 day share price return of 4.52% and a 90 day share price gain of 28.66%. The 1 year total shareholder return of 14.36% contrasts with weaker 3 and 5 year total shareholder returns, hinting at momentum that is only starting to rebuild after a tough few years.
Scan how Genmab’s rebound compares with other potential momentum rebuild stories in our hand picked 618 high quality undiscovered gems across the market.
After a sharp 90 day climb and only a modest 1 year gain, Genmab now sits at DKK 2,083. Does that recent rebound still leave enough potential upside to justify the risk based on current valuation metrics?
Most Popular Narrative: 15.1% Undervalued
Genmab’s most followed valuation story points to a fair value of DKK 2,454 against the last close at DKK 2,083, which frames the recent price rebound as only part of the move implied by that model.
Strong recurring royalty streams from established partnered products (such as DARZALEX) and a rising contribution from wholly owned product sales underpin stable, predictable cash flows. This provides financial flexibility for pipeline investment and margin expansion.
Want to see how that cash flow engine is expected to evolve? The narrative leans on rising margins, faster top line growth than the wider Danish market, and a lower future earnings multiple than many peers.
Result: Fair Value of DKK 2,454 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Genmab’s reliance on partnered products like DARZALEX, along with the risk of weaker than expected trial outcomes for key pipeline assets, could quickly challenge this undervaluation story.
Find out about the key risks to this Genmab narrative.
Another View: What Genmab’s P/E Is Telling You
A different lens on Genmab comes from its P/E ratio. At 24.5x, it sits higher than both the European biotech industry at 22.3x and a peer average of 15.2x, yet it is below an estimated fair ratio of 26.7x.
That mix points to a stock that is richly priced against peers but not stretched against its own earnings profile. This leaves investors weighing whether the premium reflects quality or simply adds more downside risk if expectations slip.
To see how this price tag lines up with the underlying numbers, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around Genmab can feel unclear, so move quickly to test the assumptions, weigh the concerns, and balance the upside against the 2 key rewards and 3 important warning signs
Looking for more Genmab sized investment ideas?
If you are weighing Genmab and do not check other live opportunities, you risk missing setups that better fit your goals and risk comfort.
- Target potential mispricing by scanning our 184 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect the underlying business.
- Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (193 results) that can help you focus on companies with sturdier financial footing.
- Balance income needs and risk by assessing a 166 dividend fortresses that screens for higher yields without ignoring financial strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com